Waldencast

WALD

Market cap $133M

The clinically proven formula pairs NAD+ with its precursors to replenish skin cells and address nine signs of skin aging for healthier, more resilient-looking skin The clinically proven formula pairs NAD+ with its precursors to replenish skin cells and address nine signs of skin aging for healthier, more resilient-looking skin

ProMD's multi-location physician led network will participate in Obagi's ALOHA Program as part of a structured evaluation of MagIQ and integrated skincare protocols to providers across multiple states ProMD's multi-location physician led network will participate in Obagi's ALOHA Program as part of a structured evaluation of MagIQ and integrated skincare protocols to providers across multiple states

FY 2025 net revenue of $272.1 million, flat to FY 2024, and Adjusted EBITDA of $16.1 million Q4 2025 net revenue of $72.0 million, flat to Q4 2024 and Adjusted EBITDA of $6.6 million Obagi Medical sees continued revenue acceleration as a result of transformation efforts and continued brand momentum, alongside investments supporting the recent launch of its injectables platform Milk Makeup maintains U.S. consumption growth through distribution expansion, offset by softness in international markets Waldencast advanced its strategic priorities in 2025, entering medical aesthetics, and strengthening its financial flexibility through the sale of the Obagi Japan trademark and the refinancing of its credit facility. As a result, the Company enters 2026 with a strong foundation for successful growth LONDON, March 13, 2026 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), a global multi-brand beauty and wellness platform, today reported operating results for the three months ended December 31, 2025 (“Q4 2025”) and year ended December 31, 2025 (“Year Ended 2025”) on Form 6-K to the U.S. Securities and Exchange Commission (the “SEC”), which are also available on our investor relations site at http://ir.waldencast.com/.

LONDON, March 11, 2026 (GLOBE NEWSWIRE) -- Waldencast plc, (NASDAQ: WALD) (“Waldencast”), a global multi-brand beauty and wellness platform announced that its Fourth Quarter and Fiscal Year 2025 earnings will be issued in a press release on March 13, 2026, prior to U.S. market open. The Company does not plan to host a conference call to discuss results given its ongoing strategic review.

Schweiger selected as a leading dermatology platform partner due to its commitment to clinical excellence, rapid access to care, and dissemination across its extensive national network of practices Schweiger selected as a leading dermatology platform partner due to its commitment to clinical excellence, rapid access to care, and dissemination across its extensive national network of practices

It's a Secret Med Spa selected as a premier luxury med spa partner due to its commitment to excellence, personalized luxury aesthetic experiences, and outstanding patient results across its growing network of high-end locations It's a Secret Med Spa selected as a premier luxury med spa partner due to its commitment to excellence, personalized luxury aesthetic experiences, and outstanding patient results across its growing network of high-end locations

Aesthetic Record selected as a leading aesthetics EMR and practice management partner due to its commitment to technology innovation, operational efficiency, and supporting thousands of aesthetic practices nationwide Aesthetic Record selected as a leading aesthetics EMR and practice management partner due to its commitment to technology innovation, operational efficiency, and supporting thousands of aesthetic practices nationwide

DermFx selected as a leading regional med spa partner due to its commitment to exceptional patient care, aesthetic innovation, and excellence across Southern California practices DermFx selected as a leading regional med spa partner due to its commitment to exceptional patient care, aesthetic innovation, and excellence across Southern California practices

Moxie selected as a leading aesthetic practice software and support partner for its commitment to innovation, compliance, and empowering aesthetic entrepreneurs Moxie selected as a leading aesthetic practice software and support partner for its commitment to innovation, compliance, and empowering aesthetic entrepreneurs

The dermatologist-tested duo pairs gentle chemical resurfacing with daily hydration and SPF protection for visibly smoother lips The dermatologist-tested duo pairs gentle chemical resurfacing with daily hydration and SPF protection for visibly smoother lips